Dr. Reddy’s Laboratories has launched generic Bosutinib tablets in the United States, according to company statements reported by multiple outlets. The drug is marketed as a generic version of bosutinib, an oncology medicine used in certain cancer-related treatments. Dr. Reddy’s says it has collaborated with MSN Laboratories for the Bosutinib product. MSN Laboratories is described as responsible for the development and manufacturing of the tablets. The reports indicate the launch is tied to the manufacturing and supply role played by MSN, while Dr. Reddy’s handles the market introduction in the U.S. The information comes from the companies’ announcements, with both sources aligning on the same key points: the U.S. launch by Dr. Reddy’s and the partnership with MSN Laboratories for development and manufacturing of Bosutinib tablets. No additional details such as pricing, regulatory milestones, or specific prescribing details are provided in the excerpts.